GlaxoSmithKline PLC, Ten Percent Owner at Innoviva, holds 16.78M shares in Wave Life Sciences (Ticker: WVE), holds 0.00 shares in Theravance Biopharma (Ticker: TBPH), holds 1.01M shares in CVRx (Ticker: CVRX). Most recently, GlaxoSmithKline PLC Bought ― shares of Wave Life Sciences on Oct 01, 2024 for an estimated value of 22.34M.
What was GlaxoSmithKline PLC’s latest transaction?
GlaxoSmithKline PLC latest transaction was an Informative Buy of $22.34M.
What was GlaxoSmithKline PLC's most profitable transaction?
GlaxoSmithKline PLC’s most profitable transaction was an Informative Buy of WVE stock on January 30, 2024. The return on the trade was 281.40%.
What is GlaxoSmithKline PLC's role in Innoviva?
GlaxoSmithKline PLC's role in Innoviva is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.